Special Survey for Long Term Application

Novo Nordisk

Status: Completed

Conditions: Achondroplasia; Genetic Disorder

Treatments: Drug: somatropin

Study type: Observational

Funder types: Industry

Identifiers

NCT01516229

GH-1941

Details and patient eligibility

About

This study is conducted in Japan. The aim of this study is to assess the incidence rate of adverse drug reactions (ADRs) when using somatropin (Norditropin®) for treatment of for achondroplasia without epiphyseal line closure under normal clinical practice conditions.

Enrollment: 395 patients

Sex: All

Ages: 1 to 15 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Achondroplasia without epiphyseal line closure

Trial design

395 participants in 1 patient group

Somatropin

Treatment:

Drug: somatropin